FY2025 EPS Estimate for Krystal Biotech Decreased by Analyst

Key Points

• Cantor Fitzgerald has reduced its FY2025 earnings per share (EPS) forecast for Krystal Biotech from $4.85 to $4.79, while the consensus estimate remains at $6.14.
• Several analysts maintain a "buy" rating for the stock, with price targets ranging from $166.00 to $240.00, indicating positive sentiment despite the downgraded EPS forecast.
• Krystal Biotech reported strong recent earnings, with $1.29 EPS for the quarter, surpassing the estimated $1.08.

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Cantor Fitzgerald dropped their FY2025 earnings estimates for shares of Krystal Biotech in a report released on Tuesday, August 5th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings of $4.79 per share for the year, down from their previous estimate of $4.85. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. Cantor Fitzgerald also issued estimates for Krystal Biotech's FY2026 earnings at $7.35 EPS.

Several other analysts have also recently issued reports on the stock. Chardan Capital reissued a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research note on Tuesday, August 5th. HC Wainwright reissued a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Friday, July 25th. Citigroup reissued a "neutral" rating and set a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Bank of America lowered their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Finally, Guggenheim lowered their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Krystal Biotech has a consensus rating of "Buy" and a consensus price target of $210.22.

Krystal Biotech Stock Up 1.9%

Shares of NASDAQ KRYS traded up $2.56 during trading on Wednesday, hitting $138.66. 332,066 shares of the company traded hands, compared to its average volume of 422,365. Krystal Biotech has a 1 year low of $122.80 and a 1 year high of $207.84. The company has a 50-day moving average price of $141.94 and a 200-day moving average price of $155.38. The firm has a market capitalization of $4.01 billion, a P/E ratio of 28.18 and a beta of 0.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.08 by $0.21. The firm had revenue of $96.04 million during the quarter, compared to analysts' expectations of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Brooklyn Investment Group raised its position in shares of Krystal Biotech by 291.7% in the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after purchasing an additional 105 shares in the last quarter. Hantz Financial Services Inc. increased its stake in shares of Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company's stock worth $25,000 after buying an additional 179 shares during the last quarter. Twin Tree Management LP bought a new stake in shares of Krystal Biotech in the first quarter worth $29,000. Fifth Third Bancorp increased its stake in shares of Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after buying an additional 105 shares during the last quarter. Finally, First Horizon Advisors Inc. increased its stake in shares of Krystal Biotech by 212.8% in the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company's stock worth $34,000 after buying an additional 166 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the company's stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total value of $208,350.00. Following the completion of the transaction, the insider directly owned 1,508,056 shares of the company's stock, valued at $226,208,400. This represents a 0.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is currently owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).